B. Gertz

发表

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

L. Lönn, L. Sjöström, J. Svensson, 1998, The Journal of clinical endocrinology and metabolism.

Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

J. Miller, B. Gertz, J. Redfern, 2001, Journal of clinical pharmacology.

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

M. Kris, R. Gralla, B. Gertz, 1999, The New England journal of medicine.

Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.

I. Eardley, B. Gertz, K. Gottesdiener, 2000, British journal of clinical pharmacology.

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

C. Hawkey, B. Gertz, N. Calder, 2001, Gastroenterology.

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine

H. Genant, D. Eyre, B. Gertz, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical pharmacology of alendronate sodium

B. Gertz, B. Matuszewski, A. Porras, 2005, Osteoporosis International.

Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

R. Sperling, M. Konstam, B. Gertz, 2002 .

Pharmacokinetics of Alendronate

B. Gertz, S. Holland, A. Porras, 1999, Clinical pharmacokinetics.

Application of a New Serum Assay for Type I Collagen Cross-Linked N-Telopeptides: Assessment of Diurnal Changes in Bone Turnover With and Without Alendronate Treatment

S. Greenspan, J. Clemens, B. Gertz, 1998, Calcified Tissue International.

Effects of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Rofecoxib

B. Gertz, T. Marbury, K. Gottesdiener, 2003, American journal of therapeutics.

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.

H. Genant, D. Eyre, B. Gertz, 1993, The Journal of clinical endocrinology and metabolism.

Studies of the oral bioavailability of alendronate

J. Mucklow, B. Gertz, K. Lasseter, 1995, Clinical pharmacology and therapeutics.

Pharmacokinetics of Intrvenous Alendronate

V. Cocquyt, B. Gertz, H. Quan, 1999 .

Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

J. Kanis, E. McCloskey, S. Vasikaran, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pharmacokinetics of alendronate: an overview.

B. Gertz, J. Lin, G. Russell, 1999, International journal of clinical practice. Supplement.

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.

R. Warrell, A. F. Stewart, B. Gertz, 1993, Journal of Clinical Oncology.

Effect of an oral α2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus

J. Halter, W. Herman, B. Gertz, 1991 .

Effects of treatment of malignancy‐associated hypercalcemia on serum parathyroid hormone‐related protein

R. Rizzoli, G. Strewler, B. Gertz, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.

T. Gettys, B. Gertz, R. Rushakoff, 1990, The Journal of clinical endocrinology and metabolism.

Montelukast Dose Selection in 6‐ to 14‐Year‐Olds: Comparison of Single‐Dose Pharmacokinetics in Children and Adults

T. Reiss, S. Spielberg, B. Gertz, 1999, Journal of clinical pharmacology.

Renal Effects of COX-2-Selective Inhibitors

B. Gertz, D. Brater, J. Redfern, 2001, American Journal of Nephrology.

Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro.

D. Gardner, C. Deschepper, B. Gertz, 1988, The Journal of clinical investigation.

Glucocorticoid control of rat growth hormone gene expression: effect on cytoplasmic messenger ribonucleic acid production and degradation.

J. Baxter, D. Gardner, B. Gertz, 1987, Molecular endocrinology.

Thyroid hormone increases rat atrial natriuretic peptide messenger ribonucleic acid accumulation in vivo and in vitro.

D. Gardner, S. Hane, B. Gertz, 1987, Molecular endocrinology.

Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.

M. Thorner, D. Krupa, B. Gertz, 1994, The Journal of clinical endocrinology and metabolism.

MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.

B. Gertz, J. Schwartz, D. Ebel, 1997, The Journal of clinical endocrinology and metabolism.

Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men.

S. Schneider, J. Seibold, M. Thorner, 1997, The Journal of clinical endocrinology and metabolism.

Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability.

D. Webb, D. Newby, B. Gertz, 1997, British journal of clinical pharmacology.

Effects of Etoricoxib and Comparator Nonsteroidal Anti‐Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet

B. Gertz, K. Lasseter, K. Gottesdiener, 2007, Journal of clinical pharmacology.

Acute effect of ephedrine on 24-h energy balance.

K. Chen, J. Jordan, B. Gertz, 1999, Clinical science.

Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus.

M. J. Smith, J. Halter, W. Herman, 1991, Metabolism: clinical and experimental.

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

M. Thorner, G. Murphy, D. Krupa, 1997, The Journal of clinical endocrinology and metabolism.

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

S. Mohan, C. Ohlsson, J. Svensson, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869

M. Decramer, B. Gertz, M. Lichinitser, 2002, Cancer.

Effect of Multiple Doses of Montelukast, a CysLT1 Receptor Antagonist, on Digoxin Pharmacokinetics in Healthy Volunteers

B. Gertz, R. Verbesselt, A. Hecken, 1999, Journal of clinical pharmacology.

Effect of Montelukast on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

B. Gertz, J. Arnout, P. Wong, 1999, Journal of clinical pharmacology.

Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.

S. Schneider, J. Seibold, D. Krupa, 1993, Journal of Clinical Endocrinology and Metabolism.

Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329.

B. Gertz, O. Olsen, H. Worning, 1991, Scandinavian journal of gastroenterology.

Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.

B. Gertz, R. Liddle, S. Kanayama, 1989, The Journal of clinical investigation.

Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.

R. Rizzoli, B. Gertz, J. Bonjour, 1992, Bone and mineral.

Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females

B. Gertz, J. Leff, W. Malbecq, 1996, Pharmaceutical Research.

Acute effect of ephedrine on 24-h energy balance.

J. Jordan, B. Gertz, D. Robertson, 1999, Clinical science.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin‐like growth factor I axis in growth hormone–deficient children

J. Svensson, E. Codner, F. Cassorla, 2001, Clinical pharmacology and therapeutics.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

T. Schnitzer, D. Krupa, K. Cerchio, 2001, The Journal of clinical endocrinology and metabolism.

Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist

O. Wolkowitz, H. Weingartner, B. Gertz, 1990, Biological Psychiatry.

A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy.

C. Grunfeld, B. Gertz, J. Karam, 1986, JAMA.

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome

J. Jankovic, J. Jimenez-Shahed, B. Coffey, 2021, JAMA network open.

Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome

J. Jankovic, J. Jimenez-Shahed, B. Coffey, 2021, JAMA network open.

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

D. Kimmel, R. Weinstein, W. Polvino, 1997, The Journal of clinical endocrinology and metabolism.

Effects of thyroid hormone on UTP content and uridine kinase activity of rat heart and skeletal muscle.

B. Gertz, N. Haugaard, E. S. Haugaard, 1980, The American journal of physiology.

Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man.

D. Webb, D. Newby, B. Gertz, 1999, British journal of clinical pharmacology.

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

B. Gertz, B. Keymeulen, J. Schwartz, 2000, Clinical pharmacology and therapeutics.

Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

R. Sperling, M. Konstam, B. Gertz, 2001, Circulation.

Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor

C. Hawkey, S. Waldman, L. DeTora, 2003, Journal of clinical pharmacology.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

R. Sperling, B. Gertz, M. Weir, 2003, American heart journal.

Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model

D. Riendeau, J. Seibold, B. Gertz, 1999, Clinical pharmacology and therapeutics.

Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

S. Waldman, B. Gertz, T. Prueksaritanont, 1999, Journal of clinical pharmacology.

Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women

D. Kimmel, R. Weinstein, W. Polvino, 1997 .

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

M. Decramer, J. Schellens, J. Schellens, 2001, European journal of cancer.

Rationale for the use of alendronate in osteoporosis

J. Kanis, S. Ortolani, B. Gertz, 2005, Osteoporosis International.

Effect of diabetes and fasting on the uridine triphosphate content and uridine kinase activity of rat cardiac and skeletal muscle.

B. Gertz, E. S. Haugaard, 1979, Metabolism: clinical and experimental.

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number.

K. Kovacs, J. Tyrrell, M. Dallman, 1987, Endocrinology.

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers

B. Gertz, J. Arnout, J. Schwartz, 2000, Journal of clinical pharmacology.

GlobalAlcoholProducers,Science,andPolicy:TheCase oftheInternationalCenterforAlcoholPolicies

B. Gertz, A. Reicin, R. Sperling, 2012 .

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

T. Schnitzer, C. Fisher, L. DeTora, 2002, Rheumatology.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

C. Lines, B. Gertz, D. Borenstein, 2002, The Journal of rheumatology.

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

D. B. Rodgers, C. Lines, B. Gertz, 2002, BMC family practice.

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

B. Gertz, R. Lins, J. Schwartz, 2001, Journal of clinical pharmacology.

Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects

B. Gertz, S. Adcock, J. Schwartz, 2003, Journal of clinical pharmacology.

The Role of Clinical Pharmacology and of Pharmacokinetics in The Development of Alendronate - A Bone Resorption Inhibitor

B. Gertz, A. Porras, 2004 .

152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents

J. Jankovic, B. Coffey, B. Gertz, 2020, CNS Spectrums.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

T. Schnitzer, F. Wolfe, M. Weisman, 1999, The Journal of rheumatology.

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

G. FitzGerald, B. Gertz, S. Kapoor, 1999, The Journal of pharmacology and experimental therapeutics.

Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet

S. Swan, B. Gertz, D. Brater, 2000, Annals of Internal Medicine.

Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.

R R Miller, B H Arison, S K Balani, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.

T. Olah, W. Polvino, B. Gertz, 1997, British journal of clinical pharmacology.

Oral Administration of the Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults

J. Bolognese, D. Krupa, K. Cerchio, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion.

D. Krupa, B. Gertz, D. Sciberras, 1994, The Journal of clinical endocrinology and metabolism.

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

B. Gertz, M. Constanzer, A. van Hecken, 1996, The Journal of clinical endocrinology and metabolism.

A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents

J. Bolognese, R. Sperling, D. Krupa, 2002, Current medical research and opinion.

Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans

K. Grasing, B. Gertz, S. Adcock, 1999, Clinical pharmacology and therapeutics.

Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.

S. Greenspan, B. Gertz, S. Holland, 1996, Proceedings of the Association of American Physicians.

Effects of five daily 1 h infusions of alendronate in paget's disease of bone

J. Kanis, B. Gertz, W. Tindale, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pharmacokinetic Evaluation of Rofecoxib

B. Gertz, K. Lasseter, Sheila A. Merschman, 2003, Clinical drug investigation.

Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain.

B. Gertz, K. Gottesdiener, Martha Huntington, 1999, Clinical therapeutics.

Demonstration of specific COX‐2 inhibition by MK‐966 in humans with supratherapeutic doses

B. Gertz, E. Ehrich, A. van Hecken, 1999 .

Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 [MK], on digoxin [DG] serum concentrations

B. Gertz, R. Lins, J. Schwartz, 1998 .

The effect of alendronate on renal tubular reabsorption of phosphate.

J. Kanis, E. McCloskey, S. Vasikaran, 1994, Bone and Mineral.

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

D. Clemmons, B. Gertz, M. Murphy, 1998, The Journal of clinical endocrinology and metabolism.